PRIMO 2024 | The evolution of immunotherapy in brain tumor treatment

Glenn Lesser, MD, Wake Forest School of Medicine, Winston-Salem, NC, discusses the journey of immunotherapy in the treatment of brain tumors. Despite initial excitement and promising case reports, numerous studies on vaccine-based approaches and immune checkpoint inhibitors yielded disappointing results, with the majority showing no significant benefits. Current challenges include the highly immunosuppressive microenvironment of gliomas, induced lymphocytopenia from standard therapies, and the immunosuppressive effects of corticosteroids. However, advancements in understanding the tumor microenvironment and ongoing research into novel approaches, such as combination therapies and targeted antigen manipulation, offer hope for the future. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.